Literature DB >> 3791558

Survival of rat mammary tumor cell clones and DNA strand damage following adriamycin treatment.

D P Evans, R E Meyn, S P Tomasovic.   

Abstract

Tumor cell subpopulations have been shown to be heterogeneous in a number of phenotypic characteristics, including responses to cytotoxic drugs. This phenotypic heterogeneity has been used here to study mechanisms associated with Adriamycin (doxorubicin HCl)-induced cytotoxicity. Clonogenic survival and alkaline elution methods were employed to examine the response of two tumor cell subpopulations to Adriamycin. The cells were derived from a primary 13762NF rat mammary adenocarcinoma (clone MTC) and a lung metastasis in the same animal (clone MTLn3). The MTC cells were significantly more resistant to Adriamycin than were the MTLn3 cells; the dose effective in reducing cell survival by 50% was 10-fold higher. Protein-associated DNA strand breakage assayed by alkaline elution was dose-dependent in both clones, and MTC cells were again more resistant to break induction than were MTLn3. These results showed that clonal tumor subpopulations isolated from a primary tumor and its metastases possessed different intrinsic survival responses to Adriamycin treatment in vitro and that this survival response correlated with Adriamycin-induced production of protein-associated DNA single-strand breaks.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3791558     DOI: 10.1007/bf00262283

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Fractionation of DNA from mammalian cells by alkaline elution.

Authors:  K W Kohn; L C Erickson; R A Ewig; C A Friedman
Journal:  Biochemistry       Date:  1976-10-19       Impact factor: 3.162

2.  DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.

Authors:  H S Schwartz
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1975-01

3.  Effects of dimethyl sulfoxide and thiourea upon intercalator-induced DNA single-strand breaks in mouse leukemia (L1210) cells.

Authors:  Y Pommier; L A Zwelling; M R Mattern; L C Erickson; D Kerrigan; R Schwartz; K W Kohn
Journal:  Cancer Res       Date:  1983-12       Impact factor: 12.701

4.  Phenotypic drift and heterogeneity in response of metastatic mammary adenocarcinoma cell clones to adriamycin, 5-fluoro-2'-deoxyuridine and methotrexate treatment in vitro.

Authors:  D R Welch; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1983 Oct-Dec       Impact factor: 5.150

5.  Multiple phenotypic divergence of mammary adenocarcinoma cell clones. II. Sensitivity to radiation, hyperthermia and FUdR.

Authors:  D R Welch; D P Evans; S P Tomasovic; L Milas; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1984 Oct-Dec       Impact factor: 5.150

Review 6.  The anthracycline antineoplastic drugs.

Authors:  R C Young; R F Ozols; C E Myers
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

Review 7.  Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review.

Authors:  G Aubel-Sadron; D Londos-Gagliardi
Journal:  Biochimie       Date:  1984-05       Impact factor: 4.079

8.  Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate.

Authors:  A Ramu; Z Fuks; S Gatt; D Glaubiger
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

9.  Mitochondrial membrane modifications induced by adriamycin-mediated electron transport.

Authors:  E Goormaghtigh; G Pollakis; J M Ruysschaert
Journal:  Biochem Pharmacol       Date:  1983-03-01       Impact factor: 5.858

10.  Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin.

Authors:  L A Zwelling; S Michaels; L C Erickson; R S Ungerleider; M Nichols; K W Kohn
Journal:  Biochemistry       Date:  1981-11-10       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.